Multiple effects of magnesium isoglycyrrhizinate on the disposition of docetaxel in docetaxel-induced liver injury

Qu, Biao; Rong, Xing; Wang, Hong; Chen, Xin; Ge, Qi; Peng, Daiyin; Wang, Guangji

doi:10.1080/00498254.2016.1185195

Cited by 14 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GL mainly inhibits the expression of nuclear factor kappa-B (NF-κB) pathway, thereupon then restraining the encoding of important genes such as inflammatory cytokines, anti-apoptotic factors and cyclooxygenase-2 (COX2) ( Li S. et al, 2014 ), achieving anti-inflammatory and anti-tumor effects. Thus, GL is commonly used in treating various cancers in clinical practice ( Stecanella et al, 2021 ; Zuo et al, 2022 ), as well as in alleviating liver, lung, and kidney damage caused by cancer chemotherapy ( Orazizadeh et al, 2014 ; Qu et al, 2017 ). Meanwhile, it also has a protective effect on brain tissue in cases of global cerebral ischemia, brain injury caused by cerebral hemorrhage, and focal ischemia ( Xiong et al, 2016 ).…”

Section: Glycyrrhizic Acidmentioning

confidence: 99%

Advances in the roles of glycyrrhizic acid in cancer therapy

Zhang¹,

Sheng²,

Xiao³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Since the first 70 years of reporting cancer chemotherapy, malignant tumors have been the second most common cause of death in children and adults. Currently, the commonly used anti-cancer methods include surgery, chemotherapy, radiotherapy, and immunotherapy. Although these treatment methods could alleviate cancer, they lead to different forms of side effects and have no particularly significant effect on prolonging the patients’ life span. Glycyrrhizic acid (GL), a native Chinese herbal extract, has a wide range of pharmacological effects, such as anti-cancer, anti-inflammatory, antioxidant, and immune regulation. In this review, the anti-cancer effects and mechanisms of GL are summarized in various cancers. The inhibition of GL on chemotherapy-induced side effects, including hepatotoxicity, nephrotoxicity, genotoxicity, neurotoxicity and pulmonary toxicity, is highlighted. Therefore, GL may be a promising and ideal drug for cancer therapy.

show abstract

Section: Glycyrrhizic Acidmentioning

confidence: 99%

Advances in the roles of glycyrrhizic acid in cancer therapy

Zhang¹,

Sheng²,

Xiao³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Its mechanism of action in humans remains to be fully elucidated, however, scavenging of free radicals, prevention of the increase of serum transaminase, reduction of hepatocyte degeneration, necrosis and inflammatory cell infiltration might be included (Wang et al, 2019;Niu et al, 2021). Previous research has shown that MgIG has antiinflammatory, antioxidant, and hepatoprotective activity in toxin-associated liver injury and hepatitis (Jiang et al, 2017a;Qu et al, 2017;Zou et al, 2018). Experimental studies in rodents demonstrated protective action against methotrexate, cyclophosphamide, paclitaxel, lipopolysaccharide, concanavalin A, ethanol, and free fatty acid (Cheng et al, 2009;Chen et al, 2014;Yang et al, 2016;Jiang et al, 2017a;Jiang et al, 2017b;Lu et al, 2017;Cao et al, 2019).…”

Section: Magnesium Isoglycyrrhizinatementioning

confidence: 99%

Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Many drugs with different mechanisms of action and indications available on the market today are capable of inducing hepatotoxicity. Drug-induced liver injury (DILI) has been a treatment challenge nowadays as it was in the past. We searched Medline (via PubMed), CENTRAL, Science Citation Index Expanded, clinical trials registries and databases of DILI and hepatotoxicity up to 2021 for novel therapies for the management of adult patients with DILI based on the combination of three main search terms: 1) treatment, 2) novel, and 3) drug-induced liver injury. The mechanism of action of novel therapies, the potential of their benefit in clinical settings, and adverse drug reactions related to novel therapies were extracted. Cochrane Risk of bias tool and Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment approach was involved in the assessment of the certainty of the evidence for primary outcomes of included studies. One thousand three hundred seventy-two articles were identified. Twenty-eight articles were included in the final analysis. Eight randomized controlled trials (RCTs) were detected and for six the available data were sufficient for analysis. In abstract form only we found six studies which were also anaylzed. Investigated agents included: bicyclol, calmangafodipir, cytisin amidophospate, fomepizole, livina-polyherbal preparation, magnesium isoglycyrrhizinate (MgIG), picroliv, plasma exchange, radix Paeoniae Rubra, and S-adenosylmethionine. The primary outcomes of included trials mainly included laboratory markers improvement. Based on the moderate-certainty evidence, more patients treated with MgIG experienced alanine aminotransferase (ALT) normalization compared to placebo. Low-certainty evidence suggests that bicyclol treatment leads to a reduction of ALT levels compared to phosphatidylcholine. For the remaining eight interventions, the certainty of the evidence for primary outcomes was assessed as very low and we are very uncertain in any estimate of effect. More effort should be involved to investigate the novel treatment of DILI. Well-designed RCTs with appropriate sample sizes, comparable groups and precise, not only surrogate outcomes are urgently welcome.

show abstract

“…SIRT1, an inhibitory transcriptional factor for the NLRP3 inflammasome, is reported to act as a protective mediator for DILI [ 14 ]. Docetaxel, a chemotherapeutic drug widely applied for the treatment of malignant tumors, is reported to induce severe liver injury during clinical treatments [ 15 , 16 ]. It is of great significance to develop effective therapies for the DILI during the Docetaxel treatments.…”

Section: Introductionmentioning

confidence: 99%

Zafirlukast ameliorates Docetaxel-induced activation of NOD-like receptor protein 3 (NLRP3) inflammasome, mediated by sirtuin1 (SIRT1) in hepatocytes

2021

View full text Add to dashboard Cite

Docetaxel-associated liver injury has become a serious public health problem, resulting in therapy discontinuation, liver failure, and death. Zafirlukast is a typical leukotriene receptor antagonist used for prophylaxis and chronic treatment of asthma. In this study, we investigate whether treatment with Zafirlukast could alleviate Docetaxel-induced cytotoxicity in hepatocytes. Our results indicate that Zafirlukast mitigated Docetaxel-induced toxicity in LO-2 hepatocytes. Firstly, Zafirlukast reduced the production of 8-hydroxy-2p-deoxyguanosine (8-OHdG) and increased the levels of reduced glutathione (GSH) against Docetaxel. Secondly, Zafirlukast elevated the levels of mitochondrial membrane potential (ΔΨm) and adenosine triphosphate (ATP). Thirdly, Zafirlukast prevented Docetaxel-induced release of lactate dehydrogenase (LDH) and increased cell viability of LO-2 hepatocytes against Docetaxel. We also found that Zafirlukast ameliorated Docetaxel-induced apoptosis by reducing Caspase-3 and Caspase-9 activity. Mechanistically, our results demonstrate that Zafirlukast inhibited the activation of NOD-like receptor protein 3 (NLRP3), mediated by SIRT1. Based on these findings, we conclude that the administration of Zafirlukast might have a protective effect against Docetaxel-induced cytotoxicity in hepatocytes.

show abstract

Multiple effects of magnesium isoglycyrrhizinate on the disposition of docetaxel in docetaxel-induced liver injury

Cited by 14 publications

References 34 publications

Advances in the roles of glycyrrhizic acid in cancer therapy

Advances in the roles of glycyrrhizic acid in cancer therapy

Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review

Zafirlukast ameliorates Docetaxel-induced activation of NOD-like receptor protein 3 (NLRP3) inflammasome, mediated by sirtuin1 (SIRT1) in hepatocytes

Contact Info

Product

Resources

About